Skip to main content
Equibles

NSRX · Nasus Pharma Ltd

Track NSRX — free

Use NSRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NSRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.39 +0.07 (+2.11%)
Rebalance outlook locked
Market Cap
$38.89M
Shares
11.71M
Volume · Oct 28 610 Avg daily vol (3M) 17.84K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.32 Open$3.28 Day$3.28–3.50 52W close$2.01–9.15 Avg vol 30d23K Short int80K · 0.7% float · 4.7d Short vol19% DataAug 2025–Oct 2026

Latest filings

6-K filed Oct 8, 2026

On October 8, 2026, Nasus Pharma Ltd. shareholders approved all meeting agenda items by the applicable required majority, except Proposal No. 4; a quorum was present.

Read the 6-K
20-F filed Mar 25, 2026
Read the 20-F
All filings

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$10.55M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-0.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.0%
Year over year · more shares
Price change (1Y)
-58.2%
Trailing year
Short interest
0.7%
Latest settlement · 4.7 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 17.5 · elevated Equity put/call 0.59
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −8%
below
RSI (14) 46
neutral
MACD trend Positive
52-week position 18%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Weak
1-month return −7%
trailing
6-month return +6%
trailing
YTD return −64%
this year
Relative strength +1%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.69% of float · ▲ +2.8% MoM · 4.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
10 holders — near 1-yr high, broad support
Squeeze score 53
elevated · 0–100
Fundamentals
Poor
EPS growth −227%
Y/Y
Free cash flow $-4.9M
Quant / Vol
risk profile
Very High
Volatility 102%
annualized · 1-yr
Max drawdown −78%
past year
ATR 8.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
46 Neutral
MACD trend
Positive Bullish
52-week position
18% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.69% of float · ▲ +2.8% MoM · 4.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
10 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $3 · 18% Range high $9
vs 200-day avg -11% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NSRX
Nasus Pharma Ltd
this stock
$38.89M -63.7% — — 0.7%
LLY
ELI LILLY & Co
 $1.21T +19.3% +44.7% 43.0 0.7%
JNJ
Johnson & Johnson
 $646.92B +29.9% +6.0% 40.8 0.7%
ABBV
AbbVie Inc.
 $505.91B +25.3% +8.6% 80.9 0.9%
MRK
Merck & Co., Inc.
 $349.89B +34.7% +1.3% 113.5 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
10
% held
18.4%
Net QoQ
-23.9K sh
Top holder
Balyasny Asset Management…
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
80.4K
Days to cover
4.7d
Change
+2.2K sh
View
Short Volume
Short vol %
19%
As of
Oct 27, 2026
Short Total
View
Fails to Deliver
FTD shares
460
Value
$1.6K
As of
Sep 28, 2026
View
Off-Exchange
Off-exchange %
65.1%
Week of
Sep 21, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.2B
Net income (FY)
$-5.9M
EPS diluted
$-0.72
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 8, 2026
This year
20

On October 8, 2026, Nasus Pharma Ltd. shareholders approved all meeting agenda items by the applicable required majority, except Proposal No. 4; a quorum was present.

View
Exempt Offerings
Offering
$15.0M
Filed
Feb 25, 2026
View

Performance

5D 20D 120D MTD YTD
NSRX +2.5% -7.0% +5.7% -10.0% -63.7%
SPY +0.1% +0.7% +4.9% +0.9% +12.9%
vs SPY +2.4% -7.7% +0.9% -11.0% -76.6%
Key facts CIK 2029039 CUSIP M7071P109 Visit website Investor relations